Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial
- Lockman Shahin
- Hughes Michael
- Sawe Fred
- Zheng Yu
- McIntyre James
- Chipato Tsungai
- Asmelash Aida
- Rassool Mohammed
- Kimaiyo Sylvester
- Shaffer Douglas
- Hosseinipour Mina
- Mohapi Lerato
- Ssali Francis
- Chibowa Margret
- Amod Farida
- Halvas Elias
- Hogg Evelyn
- Alston-Smith Beverly
- Smith Laura
- Schooley Robert
- Mellors John
- Currier Judith
DOIAbstract
Nevirapine (NVP) is widely used in antiretroviral treatment (ART) of HIV-1 globally. The primary objective of the AA5208/OCTANE trial was to compare the efficacy of NVP-based versus lopinavir/ritonavir (LPV/r)-based initial ART.<0.001). VF, death, or permanent treatment discontinuation occurred in 80 (32%) of NVP and 54 (22%) of LPV/r arms (HR = 1.7, 95% CI 1.2–2.4), with the difference primarily due to more treatment discontinuation in the NVP arm. 13 (45%) of 29 women tested in the NVP versus six (15%) of 40 in the LPV/r arm had any drug resistance mutation at time of VF..Please see later in the article for the Editors' Summar
Add to ORKG